Literature DB >> 1527047

Oligosaccharide structures of mucins secreted by the human colonic cancer cell line CL.16E.

C Capon1, C L Laboisse, J M Wieruszeski, J J Maoret, C Augeron, B Fournet.   

Abstract

Cl.16E, a stably differentiated clonal derivative of the human colonic cancer cell line HT29, was used to investigate the structure of oligosaccharide chains of mucins in colonic cancer. Secretory mucins were purified by equilibrium density gradient centrifugation in CsCl. Oligosaccharide side chains were isolated after beta-elimination. Compositional analysis of oligosaccharide-alditols performed after purification by gel filtration on a Bio-gel P-6 column showed 1) that GalNAc residues were located exclusively at the reducing ends of the chains, and 2) that fucose was absent from the preparation. Oligosaccharide-alditols were separated by high performance liquid chromatography (HPLC) on quaternary amine packings into a minor neutral fraction representing about 6.5% by weight of released oligosaccharides and four acidic fractions. Two acidic fractions, namely FI and FII encompassing mono- and disialylated structures, respectively, and containing 78% of total oligosaccharide alditols, were separated by HPLC. Structural determinations were carried out using methylation analysis, 1H NMR spectroscopy, and fast atom bombardment-mass spectrometry. Twelve oligosaccharide structures were determined which ranged in size from 3 to 8 residues. These oligosaccharides were based on core types 1, 2, and 4. Elongation of oligosaccharide chains was terminated by addition of sialic acid in alpha 2-3 linkage to Gal beta 1-3R and to Gal beta 1-4R residues. The predominant structure was a hexasaccharide (fraction FII-4). This contrasts with normal colonic mucins whose oligosaccharides were previously found to be based on core 3 structures and carry sialic acids in alpha (2-6) linkage to Gal beta 1-3R, to Gal beta 1-4R, and to GalNAc alpha-R (Podolsky, D.K. (1985) J. Biol. Chem. 260, 8262-8271; Podolsky, D.K. (1985) J. Biol. Chem. 260, 15510-15515). Collectively our findings suggest that Cl.16E colon cancer cells are able to synthesize mucin oligosaccharides of gastric type whose elongation is truncated by premature sialylation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527047

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Glycosylation-site-selective synthesis of N-acetyl-lactosamine repeats in bis-glycosylated human lysozyme.

Authors:  R Melcher; A Hillebrand; U Bahr; B Schröder; M Karas; A Hasilik
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  Characterization of novel O-glycans isolated from tear and saliva of ocular rosacea patients.

Authors:  Sureyya Ozcan; Hyun Joo An; Ana C Vieira; Gun Wook Park; Jae Han Kim; Mark J Mannis; Carlito B Lebrilla
Journal:  J Proteome Res       Date:  2013-02-06       Impact factor: 4.466

4.  Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation.

Authors:  P Delannoy; I Kim; N Emery; C De Bolos; A Verbert; P Degand; G Huet
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

5.  Mucins secreted by a transformed cell line derived from human tracheal gland cells.

Authors:  J M Lo-Guidice; M D Merten; G Lamblin; N Porchet; M C Houvenaghel; C Figarella; P Roussel; J M Perini
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

6.  Increased elongation of N-acetyllactosamine repeats in doubly glycosylated lysozyme with a particular spacing of the glycosylation sites.

Authors:  R Melcher; H W Grosch; O Grosse; A Hasilik
Journal:  Glycoconj J       Date:  1998-10       Impact factor: 2.916

7.  Alpha1,4GlcNAc-capped mucin-type O-glycan inhibits cholesterol alpha-glucosyltransferase from Helicobacter pylori and suppresses H. pylori growth.

Authors:  Heeseob Lee; Ping Wang; Hitomi Hoshino; Yuki Ito; Motohiro Kobayashi; Jun Nakayama; Peter H Seeberger; Minoru Fukuda
Journal:  Glycobiology       Date:  2008-05-05       Impact factor: 4.313

Review 8.  Carbohydrate-dependent defense mechanisms against Helicobacter pylori infection.

Authors:  Motohiro Kobayashi; Heeseob Lee; Jun Nakayama; Minoru Fukuda
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

9.  Divergent mechanisms of interaction of Helicobacter pylori and Campylobacter jejuni with mucus and mucins.

Authors:  Julie Ann Naughton; Karina Mariño; Brendan Dolan; Colm Reid; Ronan Gough; Mary E Gallagher; Michelle Kilcoyne; Jared Q Gerlach; Lokesh Joshi; Pauline Rudd; Stephen Carrington; Billy Bourke; Marguerite Clyne
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

10.  Permanent exposure of mucin-secreting HT-29 cells to benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation of mucins and inhibits constitutive and stimulated MUC5AC secretion.

Authors:  S Hennebicq-Reig; T Lesuffleur; C Capon; C De Bolos; I Kim; O Moreau; C Richet; B Hémon; M A Recchi; E Maës; J P Aubert; F X Real; A Zweibaum; P Delannoy; P Degand; G Huet
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.